Annexin Pharmaceuticals AB (ANNX) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.716x

Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has a cash flow conversion efficiency ratio of -0.716x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.33 Million ≈ $-1.11 Million USD) by net assets (Skr14.42 Million ≈ $1.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Annexin Pharmaceuticals AB (ANNX) total market value for the company's overall valuation and market capitalisation.

Annexin Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Annexin Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Annexin Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Annexin Pharmaceuticals AB ranked by their cash flow conversion efficiency. See Annexin Pharmaceuticals AB cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
ChargePanel AB ST:CHARGE	-0.513x
U-BX Technology Ltd. Ordinary Shares NASDAQ:UBXG	-0.017x
Immuron Ltd AU:IMC	-0.189x
BLB Limited NSE:BLBLIMITED	-0.024x
Royal Hali Iplik Tekstil Mobilya Sanayi ve Ticaret AS IS:ROYAL	-1.588x
Green Rise Capital Corp V:GRF	-0.105x
Wescan Goldfields Inc V:WGF	1.871x
Presurance Holdings, Inc. NASDAQ:PRHI	-0.027x

Annual Cash Flow Conversion Efficiency for Annexin Pharmaceuticals AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of Annexin Pharmaceuticals AB from 2015 to 2025. View Annexin Pharmaceuticals AB share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr24.93 Million ≈ $2.68 Million	Skr-36.92 Million ≈ $-3.97 Million	-1.481x	+59.57%
2024-12-31	Skr13.71 Million ≈ $1.48 Million	Skr-50.23 Million ≈ $-5.41 Million	-3.663x	-58.77%
2023-12-31	Skr18.81 Million ≈ $2.02 Million	Skr-43.40 Million ≈ $-4.67 Million	-2.307x	-68.98%
2022-12-31	Skr30.15 Million ≈ $3.24 Million	Skr-41.16 Million ≈ $-4.43 Million	-1.365x	-41.68%
2021-12-31	Skr46.73 Million ≈ $5.03 Million	Skr-45.02 Million ≈ $-4.85 Million	-0.964x	+49.27%
2020-12-31	Skr20.64 Million ≈ $2.22 Million	Skr-39.20 Million ≈ $-4.22 Million	-1.899x	+15.17%
2019-12-31	Skr11.49 Million ≈ $1.24 Million	Skr-25.73 Million ≈ $-2.77 Million	-2.239x	-213.04%
2018-12-31	Skr39.85 Million ≈ $4.29 Million	Skr-28.50 Million ≈ $-3.07 Million	-0.715x	+55.27%
2017-12-31	Skr24.44 Million ≈ $2.63 Million	Skr-39.08 Million ≈ $-4.21 Million	-1.599x	-150.32%
2016-12-31	Skr15.57 Million ≈ $1.68 Million	Skr-9.95 Million ≈ $-1.07 Million	-0.639x	-101.75%
2015-12-31	Skr-137.00K ≈ $-14.74K	Skr-5.01 Million ≈ $-539.37K	36.584x	--

About Annexin Pharmaceuticals AB

ST:ANNX Sweden Biotechnology

Market Cap

$9.14 Million

Skr84.91 Million SEK

Market Cap Rank

#27399 Global

#598 in Sweden

Share Price

Skr11.85

Change (1 day)

-5.58%

52-Week Range

Skr11.85 - Skr29.60

All Time High

Skr37.00